Continuity Biosciences Acquires Focal Medical for Enhanced Cancer Treatment
Deal News | Jun 04, 2025 | PR Newswire Cision Continuity Biosciences LLC
Continuity Biosciences, LLC, a company specializing in advanced drug delivery technologies, has successfully acquired Focal Medical, Inc., a North Carolina-based biopharmaceutical company focused on site-specific chemotherapy using iontophoresis. The acquisition marks an important milestone in Continuity's goal to become a leader in device-targeted therapies for solid tumors, particularly pancreatic cancer. Focal Medical’s innovative approach delivers chemotherapy directly to tumors, enhancing local drug concentration and minimizing systemic toxicity. Their lead product, an iontophoresis device for gemcitabine therapy, has FDA clearance for Phase 1b clinical trials. Through the acquisition, Continuity gains Focal's patents, technology platform, and key personnel, thereby enhancing its portfolio and internal capabilities.
Sectors
- Biopharmaceutical
- Healthcare Technology
Geography
- United States – Both companies, Continuity Biosciences and Focal Medical, are based in the United States, and the acquisition is primarily relevant to the U.S. market.
Industry
- Biopharmaceutical – The article discusses the acquisition of a biopharmaceutical company and involves drug delivery technologies targeting cancer therapy.
- Healthcare Technology – The involvement of advanced drug delivery methods like iontophoresis positions the article within the healthcare technology sector.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Continuity Biosciences, LLC | Acquiring Company | Company | A biopharmaceutical company developing advanced drug delivery technologies. |
| Focal Medical, Inc. | Target Company | Company | A biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. |
| Ramakrishna Venugopalan | CEO | Person | Chief Executive Officer of Continuity Biosciences. |
| Jen Jen Yeh | Co-founder | Person | Co-founder of Focal Medical and a surgical oncologist and professor at UNC-Chapel Hill. |
| Joseph DeSimone | Co-founder | Person | Co-founder of Focal Medical and a professor at Stanford University. |
| Tony Voiers | Acting CEO | Person | Acting CEO of Focal Medical at the time of acquisition. |
| University of North Carolina at Chapel Hill | Partner | Organization | Involved in licensing agreements related to Focal Medical's technology. |